Publicacións nas que colabora con Francisco Javier Pavón Morón (15)

2020

  1. Differential hepatoprotective role of the cannabinoid CB1 and CB2 receptors in paracetamol-induced liver injury

    British Journal of Pharmacology, Vol. 177, Núm. 14, pp. 3309-3326

  2. Impact of intermittent voluntary ethanol consumption during adolescence on the expression of endocannabinoid system and neuroinflammatory mediators

    European Neuropsychopharmacology, Vol. 33, pp. 126-138

  3. Potential association of plasma lysophosphatidic acid (LPA) species with cognitive impairment in abstinent alcohol use disorders outpatients

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Plasma concentrations of oleoylethanolamide in a primary care sample of depressed patients are increased in those treated with selective serotonin reuptake inhibitor-type antidepressants

    Neuropharmacology, Vol. 149, pp. 212-220

2018

  1. PPARα/CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models

    Biochemical Pharmacology, Vol. 157, pp. 235-243

2017

  1. Acetaminophen-induced liver injury alters the Acyl ethanolamine-based anti-inflammatory signaling system in liver

    Frontiers in Pharmacology, Vol. 8, Núm. OCT

  2. Comorbilidad psiquiátrica y valores plasmáticos de 2-acilgliceroles en consumidores de alcohol en tratamiento ambulatorio. Análisis de las diferencias de género

    Adicciones: Revista de socidrogalcohol, Vol. 29, Núm. 2, pp. 83-96

  3. Plasma concentrations of oleoylethanolamide and other acylethanolamides are altered in alcohol-dependent patients: effect of length of abstinence

    Addiction Biology, Vol. 22, Núm. 5, pp. 1366-1377

2015

  1. Pharmacological blockade of the fatty acid amide hydrolase (FAAH) alters neural proliferation, apoptosis and gliosis in the rat hippocampus, hypothalamus and striatum in a negative energy context

    Frontiers in Cellular Neuroscience, Vol. 9

  2. Plasma Concentrations of BDNF and IGF-1 in abstinent cocaine users with high prevalence of substance use disorders: Relationship to psychiatric comorbidity

    PLoS ONE, Vol. 10, Núm. 3

  3. Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: Influence of cocaine symptom severity and psychiatric co-morbidity

    Addiction Biology, Vol. 20, Núm. 4, pp. 756-772

  4. Sex differences in psychiatric comorbidity and plasma biomarkers for cocaine addiction in abstinent cocaine-addicted subjects in outpatient settings

    Frontiers in Psychiatry, Vol. 6, Núm. FEB

  5. Treatment with a novel oleic-acid-dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats

    DMM Disease Models and Mechanisms, Vol. 8, Núm. 10, pp. 1213-1225

2013

  1. Diet-dependent modulation of hippocampal expression of endocannabinoid signaling-related proteins in cannabinoid antagonist-treated obese rats

    European Journal of Neuroscience, Vol. 37, Núm. 1, pp. 105-117

  2. Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: Impact of psychiatric co-morbidity

    Addiction Biology, Vol. 18, Núm. 6, pp. 955-969